FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA
Executive Summary
Pending drug safety legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) may do more harm than good, FDA implied in comments submitted to the Senate Health Committee
You may also be interested in...
Hassan Urges Incoming Congress To Sustain U.S. Biomedical Strength
Schering-Plough CEO Fred Hassan is urging newly elected members of Congress to help preserve the strength of the U.S. biomedical industry in the face of rising foreign competition
Hassan Urges Incoming Congress To Sustain U.S. Biomedical Strength
Schering-Plough CEO Fred Hassan is urging newly elected members of Congress to help preserve the strength of the U.S. biomedical industry in the face of rising foreign competition
Democratic Capitol Hill Will Create Challenges For Brand Industry
The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act